Exercise training and pyridostigmine each have unique benefits for patients with fibromyalgia

Commentary
Fibromyalgia is characterised by widespread pain, fatigue, stiffness, disrupted sleep, depression, physical deconditioning, and low pain thresholds at specific anatomic sites, which are termed tender points (Wolfe 1990) . Exercise or injections of growth hormone can improve fibromyalgia symptoms (Jones 2006 (Jones , 2007 . As a cheaper alternative to injections of growth hormone, the drug pyridostigmine can be used to stimulate the body's growth hormone production. This factorial trial sought to determine the benefits of exercise and pyridostigmine, alone or in combination, in patients with fibromyalgia.
This study is of excellent quality, scoring 9/10 on the PEDro scale (Maher 2003) , although the points awarded for blinding apply only to the comparison of pyridostigmine and its placebo. The control condition for the exercise comparison would not successfully blind the exercise, but would at least control for the attention from the investigators. Also, the investigators appropriately lowered the usual significance level to 0.01 to account for the large number of outcomes.
Both this study and the Cochrane systematic review of exercise for fibromyalgia (Busch 2007) found that the effect of exercise on pain was almost statistically significant. If this new study is incorporated in the next update of the review, the new meta-analysis may show that exercise significantly improves pain. Furthermore, the Cochrane review found no data on flexibility and strength, so this study adds important information about these outcomes.
However, the 4 cm improvement in seated fingertip-to-toe distance is of questionable clinical importance.
Pyridostigmine improved a different set of outcomes: sleep and anxiety. These mutually exclusive benefits of the two interventions suggest that both should be offered to fibromyalgia patients. The lack of an interaction effect confirms that the combined benefit is equivalent to the sum of the benefits of each treatment alone.
As in many long-term trials, patient compliance was disappointing, with ~30% of patients attending less than half the allocated exercise sessions. Compliance with pyridostigmine was higher, but the estimate may have been inflated because it relied on patient reports only. Nevertheless, even with this level of compliance, the results are generally clinically worthwhile.
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